Gina Columbus
CURE Magazine
Jersey Shore, PA, United States
Contact Gina
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Gina:
FDA Approves Tibsovo for Frontline IDH1-Mutant Acute Myeloid Leukemia
The FDA has approved a supplemental new drug application for Tibsovo as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia who are 75 years and older or are ineligible to receive intensive chemotherapy. → Read More
FDA Approves Ibrance to Treat Male Breast Cancer
The FDA has expanded the approval of Ibrance (palbociclib) capsules in combination with endocrine therapy for male patients with hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer. → Read More
FDA Approves Tecentriq Plus Chemo for Small Cell Lung Cancer
The Food and Drug Administration (FDA) has granted an approval to the combination of Tecentriq (atezolizumab) with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). → Read More
FDA Approves Third Herceptin Biosimilar
The FDA has granted an approval to Ontruzant (SB3; trastuzumab -dttb), a Herceptin (trastuzumab) biosimilar, for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma. → Read More
Zanubrutinib Granted Breakthrough Designation for Mantle Cell Lymphoma
The Food and Drug Administration (FDA) has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one prior therapy, according to BeiGene, the company manufacturing the agent. → Read More
FDA Approves Frontline Tecentriq Regimen for NSCLC
The Food and Drug Administration has approved Tecentriq (atezolizumab) for use in combination with Avastin (bevacizumab), carboplatin, paclitaxel, the treatment combination known as ABCP, for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). → Read More
LOXO-292 Granted Breakthrough Designation for Thyroid Cancer
The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor. → Read More
Will Immunotherapy and Radiation Be Combined in Lung Cancer Treatment?
Checkpoint inhibitors continue to show promise in the treatment of patients with non-small cell lung cancer (NSCLC), but researchers are now exploring the efficacy of these agents when combined with radiation therapy (RT). → Read More
Treatment for EGFR-Mutant Lung Cancer Is Rapidly Expanding
There has been a “renaissance” in the treatment strategies of patients with non-small cell lung cancer (NSCLC) who have EGFR-mutation–positive disease, Edward S. Kim, M.D. → Read More
Improving Treatment for Elderly Patients With Myeloma
Several questions still remain regarding the treatment strategies for elderly patients with multiple myeloma, many of whom may have other comorbidities or trouble tolerating therapies. → Read More
Better Understanding of Ovarian Cancer Is Needed, Expert Says
To better understand ovarian cancer, as well as predict when women might relapse, it is crucial that researchers start investigating more of the molecular phases of the disease, says Peter Dottino, M.D. → Read More
More Patients Can Benefit from New Ovarian Cancer Treatments
PARP inhibitors are changing the way ovarian cancer is treated. → Read More
More Expansive Genetic Testing Needed in Ovarian Cancer
More research is needed on the other genetic mutations, besides BRCA, that patients with ovarian cancer harbor so that they can be used to help plan treatments. → Read More
Expert Gives Updates on Kidney and Bladder Cancer
Sumanta Kumar Pal, M.D., associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials. → Read More
Expert Discusses Lung Cancer Gene Editing
CRISPR technology may one day lead the field in turning off genetic mutations that cause numerous diseases, such as lung cancer. CURE spoke with Monte Winslow, Ph.D., about CRISPR's current use in mouse models. → Read More
Expert Talks Advancements in Multiple Myeloma Treatment
Peter Voorhees, M.D., discusses the advancements in multiple myeloma treatment, as well as where he hopes the field will go in coming years. → Read More
Expert Talks Molecular Targets in Lung Cancer
“The goal is to identify more of these driving genetic alterations and to come up with treatments that we can target,” said Das in an interview during an interview with CURE. → Read More
Normalizing Lung Cancer Screening: Expert Weighs In
Pierre Massion, M.D., sat down with CURE to discuss lung cancer screening and prevention. → Read More
Shining a Light on Life With Lymphoma
Intellisphere, LLC 666 Plainsboro Road Building 300 Plainsboro, NJ 08536 P: 800-210-2873 Copyright © 2016 CURE Communications Group. All rights reserved. Intellisphere, LLC. All Rights Reserved. CURE does not provide medical, diagnostic, or treatment advice. → Read More
Shore rallies for girl, 5, battling cancer
5-year-old Lily Rose Cramer has been diagnosed with aggressive neuroblastoma. → Read More